The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.
about
Chronic Lymphocytic Leukemia in the Elderly, Which Investigations Are Necessary: A Map for the Practicing OncologistDeciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolutionClinical implications of the molecular genetics of chronic lymphocytic leukemiaThe biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemiaMutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without ImmunotherapyThe Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service researchThe shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data.Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks.Polyploidy in chronic lymphocytic leukemia with p53 deletion detected by fish: a case reportAn extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractorinessDetermination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemiaRadiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities.Predicting survival in chronic lymphocytic leukemia.Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemiaDetection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?Autoantibodies against p53 are associated with chromosome 17p deletions in chronic lymphocytic leukemia.Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia.The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias.Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia.An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases.Molecular pathogenesis of chronic lymphocytic leukemia.Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia.The spectrum of genetic defects in chronic lymphocytic leukemia.Using the geometric mean fluorescence intensity index method to measure ZAP-70 expression in patients with chronic lymphocytic leukemia.Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.Cystatin C as a p53-inducible apoptotic mediator that regulates cathepsin L activityDetection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia.Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlationsTreatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway.Somatic inactivation of Tp53 in hematopoietic stem cells or thymocytes predisposes mice to thymic lymphomas with clonal translocations.
P2860
Q26775986-85CD6FEC-1AD7-410A-A1A9-1A548EB02B80Q26823586-A782A033-D48D-4339-85AD-5977F59CDFACQ26830955-250C62A7-8C8E-4B36-BCAA-E04D3441319BQ27024411-559E21B0-F72A-4208-BF90-BA046F30BAF8Q27851685-23027C30-8DFB-491D-933F-E54E694668C1Q28077136-69BFF887-3551-4B73-A3CE-FEB1E056B76CQ28266484-0C8FA642-A09A-441C-959A-9759774CA262Q30243968-2FC2D671-99F5-4393-ABD0-8EEA6A022D4DQ30685440-4097AF2D-AC83-42D8-8519-82CA94D9406EQ33396594-CB0AD797-8A3B-4612-AB62-B01F8287F527Q33409459-2F33E3E8-63AC-4B8F-A431-F9F60DFD4AB8Q33439682-6CA7ECBE-7883-40D2-B534-0E90E42DC18CQ33638819-F91EE73D-7D0F-4166-B1A6-4AD01E2B72F8Q33681804-FDD6F3AD-34F2-4F9D-BBB4-82F57B105ACBQ33709543-9D8B7630-880E-4A41-8971-F36A3175E01FQ33898309-EAF437E1-B61F-4674-81C1-FCFC20B62748Q34017782-59028D2F-4F43-43B6-B226-3FA740276D6EQ34257190-F99FE942-0CBD-4EDA-8CC2-F74D78F3298EQ34453174-7BA1FDE6-D0EB-4A62-B9AF-B9049D81ABE2Q34461989-96DD3CEB-D328-406F-AB2B-523174344B7DQ34625543-ECED7294-ADF5-4732-86DA-2923697BAA7AQ35049753-3AFD8B97-3115-40DD-B3DB-0ADBE1FE8E0BQ35143490-1AA4E581-B719-44D8-99DB-C727D4DDEEEAQ35149661-8DDFE96D-E0EB-466B-A7A9-3F9FF7685B2EQ35220403-AFD29190-8CF5-4160-BC55-B1336DFB97A4Q35597328-8697ED55-1F6A-44DF-9762-DB65CFB16AB7Q35741703-59BE7E06-A74A-4201-BB81-936F0EED01F3Q35859176-9F71AA65-D5B8-4BA6-984A-8909B1D08622Q35978724-AB7C8BA1-97FB-4B5E-8203-B3FB22704191Q36290321-0FC944B0-E8C6-42FB-AD30-B651A9FBD07FQ36420752-AD6019F0-9DCD-4497-BAD2-78174F60D7D8Q36426587-DFF6ED51-3947-4F93-820A-96CD0226B810Q36603887-8FF15871-F82A-47DD-BEC1-3C3ADD0B6836Q36629141-70F2B1AF-DD0E-49E4-94C2-1DF0E0378B1CQ36734163-4B610C78-7459-46AA-8891-064F2006FFA3Q36746295-6B9447C9-91C8-405B-AD0A-93334B861AE5Q36799831-4440FB79-0D40-4FFD-AED0-FD345BB8D7FDQ37260520-7619038B-C91B-4DCA-8F96-4F13196175C2Q37434174-EAE3482F-4B91-4E48-B751-1DE58163C9FDQ37452977-7346109E-D2AE-4DA4-8E0A-14DB0C35176F
P2860
The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
The detection of TP53 mutation ...... a complex aberrant karyotype.
@en
The detection of TP53 mutation ...... a complex aberrant karyotype.
@nl
type
label
The detection of TP53 mutation ...... a complex aberrant karyotype.
@en
The detection of TP53 mutation ...... a complex aberrant karyotype.
@nl
prefLabel
The detection of TP53 mutation ...... a complex aberrant karyotype.
@en
The detection of TP53 mutation ...... a complex aberrant karyotype.
@nl
P2093
P921
P356
P1433
P1476
The detection of TP53 mutation ...... a complex aberrant karyotype.
@en
P2093
S Schnittger
P2888
P304
P356
10.1038/LEU.2008.274
P577
2008-10-09T00:00:00Z